THE ROLE OF THE TRANSCRIPTION FACTOR GFI1 IN LEUKEMIA GENOME STABILITY AND EVOLUTION

EHA Learning Center, Daria Frank, 214636

VEGFC ANTIBODY TREATMENT: A NEW DIFFERENTIATION THERAPY FOR AML

EHA Learning Center, Kim Kampen, 214637

DISTINCT DNA METHYLATION PROFILES IN DIFFERENT CYTOGENETIC SUBGROUPS OF CHRONIC LYMPHOCYTIC LEUKEMIA: THE INTRIGUING CASE OF TRISOMY 12

EHA Learning Center, MARIA TSAGIOPOULOU, 214652

BIALLELIC INACTIVATION OF ATM AND BIRC3 IN DEL(11Q) CELLS DRIVES GENOMIC INSTABILITY AND TUMOR EXPANSION IN CRISPR/CAS9-GENERATED MODELS OF CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Learning Center, Miguel Quijada Alamo, 214653

CD20 IS A DIRECT REGULATOR OF B-CELL RECEPTOR SIGNALING IN THE MICROENVIRONMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Learning Center, Gabriela Pavlasova, 214654

CHARACTERIZATION OF PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH DNA METHYLATION STATUS

EHA Learning Center, Shunsuke Kimura, 215236

THE PHILADELPHIA-LIKE SUBTYPE IN CHILDREN WITH FIRST RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: A STUDY OF THE GERMAN ALL-REZ BFM 2002 TRIAL

EHA Learning Center, Malwine Pogodzinski, 215237

HUMAN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA DEVELOPS HYPOXIA-RELATED CHEMORESISTANCE THROUGH HIF1Α AND MTOR PATHWAY INTERACTIONS

EHA Learning Center, Lucine Fahy, 215238

THE CELL SURFACE PROTEIN VANIN-2 IDENTIFIES AGGRESSIVE SUBTYPES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Learning Center, Virginia Rodriguez Martinez, 215253

NILOTINIB COMBINED WITH LOWER-INTENSITY CHEMOTHERAPY FOR FRONT-LINE TREATMENT OF YOUNGER ADULTS WITH PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): INTERIM ANALYSIS OF THE GRAAPH-2014 TRIAL

EHA Learning Center, Yves Chalandon, 215254

PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA AND MLL REARRANGEMENT SHOW A DISTINCTIVE EXPRESSION PATTERN OF HISTONE DEACETYLASES

EHA Learning Center, Nerea Vega-Garcia, 215255

PHARMACOLOGIC INHIBITION OF CELLULAR METABOLIC PROCESSES IMPACTED BY AGING SENSITIZE ACUTE MYELOID LEUKEMIA (AML) CELLS TO THE NOVEL LIPOATE DERIVATIVE CPI-613

EHA Learning Center, Timothy Pardee, 215270

GENOMIC CHARACTERIZATION OF DIAGNOSTIC AND REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA SAMPLES THROUGH A NEXT GENERATION SEQUENCING (NGS) PANEL OF 62 GENES

EHA Learning Center, Diego Carbonell, 215271

THE CALCIUM BINDING PROTEIN S100A8/S100A9 COMPLEX IS ASSOCIATED WITH DRUG RESISTANCE IN ACUTE MYELOID LEUKEMIA

EHA Learning Center, Riikka Karjalainen, 215286

A HIGH RISK PEDIATRIC AML SUBTYPE PRESENTS A DIAGNOSTIC CHALLENGE-A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP AAML0531 STUDY

EHA Learning Center, Timothy P Singleton, 215288

SINGLE CENTRE REAL-LIFE EXPERIENCE OF HYPOMETHYLATING AGENTS WITH OR WITHOUT DLI AS SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.

EHA Learning Center, Davide Lazzarotto, 215303

CONSOLIDATION CHEMOTHERAPY PREVENTS RELAPSE BY INDIRECTLY REGULATING BONE MARROW ADIPOGENESIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Learning Center, Hanyan Liu, 215304

INTRA-PATIENT DOSE-ESCALATION STUDY OF CRENOLANIB MAINTENANCE THERAPY IN PATIENTS WITH FLT3 MUTANT AML WHO HAD UNDERGONE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT)

EHA Learning Center, Betul Oran, 215319

CONSOLIDATION THERAPY WITH PONATINIB IN COMBINATION WITH CYTARABINE IN PATIENTS FOR FLT3-ITD ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION.

EHA Learning Center, Philippe Rousselot, 215320

ACALABRUTINIB IN COMBINATION WITH THE PI3Kδ INHIBITOR ACP-319 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES.

EHA Learning Center, Paul M. Barr, 215335

TIME TO RELAPSE OF MANTLE CELL LYMPHOMA AFTER INTENSIVE HIGH DOSE CYTARABINE CONTAINING REGIMENS DEFINES PATIENTS RISK FOR DEATH: AN ANALYSIS FROM CENTERS OF THE FONDAZIONE ITALIANA LINFOMI

EHA Learning Center, Carlo Visco, 215336

THE ADDITION OF ROMIDEPSIN TO CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IS FEASIBLE IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS: RESULTS OF PHASE IB FIL-PTCL13

EHA Learning Center, Annalisa Chiappella, 215351

A PHASE I, MULTICENTER, OPEN-LABEL DOSE-ESCALATION STUDY OF CC-122, A NOVEL CEREBLON-MODULATING AGENT, IN ADULT JAPANESE PATIENTS WITH ADVANCED NON-HODGKIN LYMPHOMA OR SOLID TUMOR

EHA Learning Center, Kazuhito Yamamoto, 215352

THALIDOMIDE USE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: A RETROSPECTIVE EVALUATION OF THE PATIENTS

EHA Learning Center, Mehmet Baysal, 215367

DIAGNOSIS AND MANAGEMENT OF ACQUIRED VON WILLEBRAND DISEASE. A SINGLE CENTER EXPERIENCE

EHA Learning Center, Cristina Santoro, 215368

MANAGEMENT OF PATIENTS WITH SEVERE APLASTIC ANAEMIA WHO ARE REFRACTORY TO PLATELET TRANSFUSIONS USING LEUKOCYTE CONCENTRATES

EHA Learning Center, jiali Huo, 215383

IRON OVERLOAD AND MANAGEMENT IN PATIENTS WITH DIAMOND BLACKFAN ANEMIA

EHA Learning Center, Sule Unal, 215384

DETIN: OVERCOMING TUMOR IN NORMAL CONTAMINATION.

EHA Learning Center, Amaro Taylor-Weiner, 215400

TRACKING THE MINOR CLONES IN OLIGOCLONAL CHRONIC LYMPHOCYTIC LEUKEMIA USING HIGH-THROUGHPUT IMMUNOPROFILING

EHA Learning Center, Kamila Stranska, 215401

EXPRESSION OF ANTIGENS INVOLVED IN THE FORMATION OF AN IMMUNOLOGICAL SYNAPSE IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Learning Center, Yulia Davydova, 215416

IDENTIFICATION OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AT HIGH RISK OF INFECTION OR TREATMENT THROUGH MACHINE LEARNING ALGORITHMS

EHA Learning Center, Carsten Niemann, 215417

PATIENT-SPECIFIC BCR-ABL1 GENOMIC FUSION ANALYSIS OF MINIMAL RESIDUAL DISEASE OF CML PATIENTS ELIGIBLE FOR TKI STOPPING SIGNIFICANTLY OUTPERFORMED MRNA DETECTION EITHER BY QPCR OR DIGITAL PCR

EHA Learning Center, Katerina Machova Polakova, 215432

TREATMENT-FREE REMISSION AFTER SECOND-STOP OF IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE

EHA Learning Center, Sukjoong Oh, 215433

COMBINED EMA-BINDING TEST AND OSMOTIC GRADIANT EKTACYTOMETRY SIGNIFICANTLY IMPROVE THE LABORATORY DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS

EHA Learning Center, Andreas Glenthøj, 215449

PREVALENCE AND PREDICTORS OF LIVER FIBROSIS EVALUATED BY VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY (FIBROSCAN®) IN ADULT PATIENTS WITH TYPE 1 GAUCHER DISEASE

EHA Learning Center, Maria Domenica Cappellini, 215450

HIGH BASELINE FERRITIN IS ASSOCIATED WITH GRADE 2 CRS REQUIRING TOCILIZUMAB OR GRADE ≥ 3 CRS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH BB2121 ANTI-BCMA CAR T CELLS

EHA Learning Center, Jesus Berdeja, 215465

THE COMBINATION OF CD19/BCMA-DIRECTED CART CELLS INDUCED THERAPEUTIC RESPONSE AND REVERSIBLE COMPARTMENTAL CYTOKINE RELEASE SYNDROME CONFINED TO CEREBRAL REGION IN A PATIENT WITH CNS MULTIPLE MYELOMA

EHA Learning Center, Caixia Li, 215466

VERY LATE RELAPSES (VLRS) IN HODGKIN LYMPHOMA (HL) OCCURING ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY ± RADIOTHERAPY (CT±RT): PATTERN OF RISK OVER 35 YEARS AND THE SIGNIFICANCE OF HISTOLOGY

EHA Learning Center, Theodoros Vassilakopoulos, 215481

BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE III OR IV HODGKIN LYMPHOMA: IMPACT OF CYCLE 2 PET RESULT ON MODIFIED PROGRESSION-FREE SURVIVAL

EHA Learning Center, Robert Chen, 215482

IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME

EHA Learning Center, Jorge CASTILLO, 215497

IBRUTINIB MONOTHERAPY IN SYMPTOMATIC, TREATMENT-NAIVE PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA.

EHA Learning Center, Steven Treon, 215498

THE DIAGNOSTIC UTILITY AND SENSITIVITY OF THE XPERT® MTB/RIF ASSAY IN DIAGNOSING MYCOBACTERIUM TUBERCULOSIS IN BONE MARROW ASPIRATE SPECIMENS

EHA Learning Center, Nadhiya Subramony, 215514

Clinical and microbiological profile of bloodstream infections in patients with hematological malignancies and febrile neutropenia (PS 1210).

EHA Learning Center, Haydee Bernard, 215515

IT TAKES A LOT OF IRON TO AVOID TRANSFUSION

EHA Learning Center, Magda Jabbar Al-Obaidi, 215531

PANCREATIC IRON LOADING IN EMOGLOBINOPATHIES.

EHA Learning Center, Alessia Pepe, 215532

AUTOPHAGY IN MYELODYSPLASTIC SYNDROMES: THE ROLE OF HIF-1A/REDD1 MOLECULAR PATHWAY

EHA Learning Center, Ioanna STERGIOU, 215547

AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DURVALUMAB IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AFTER TREATMENT WITH HYPOMETHYLATING AGENTS

EHA Learning Center, Guillermo Garcia-Manero, 215548

TLR4 SIGNALING DRIVES MESENCHYMAL STEM CELLS (MSC) COMMITMENT TO PROMOTE TUMOR MICROENVIRONMENT TRANSFORMATION IN MULTIPLE MYELOMA

EHA Learning Center, Cesarina Giallongo, 215564

BI-ALLELIC LOSS OF FAM46C BY CRISPR/CAS9 SYSTEM ENHANCES MYELOMA CELL GROWTH

EHA Learning Center, KANASUGI JO, 215565

TGFΒ INHIBITION IN COMBINATION WITH CHEMOTHERAPY REPAIRS EXISTING LYTIC BONE LESIONS IN A NOVEL PLATEAU PHASE MODEL OF MULTIPLE MYELOMA

EHA Learning Center, Andrew Chantry, 215580

MULTIPLE MYELOMA: SINGLE PLARFORM ABSOLUTE COUNT OF CIRCULATING PLASMA CELLS AT DIAGNOSIS CORRELATE WITH POOR PROGNOSIS PARAMETERS.

EHA Learning Center, Vittorio Emanuele Muccio, 215581

CARFILZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE IN TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PRELIMINARY RESULT OF SGHMM1 TRIAL, HIGH-RISK COHORT (NCT02217163)

EHA Learning Center, Chandramouli Nagarajan, 215596

WEEKLY CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): A PHASE 1B STUDY

EHA Learning Center, Noa Biran, 215597

NOVEL THERAPIES DIFFERENTIALLY IMPACT POLYCLONAL IMMUNOGLOBULIN RECOVERY IN MYELOMA PATIENTS: A LONGITUDINAL STUDY

EHA Learning Center, Mauricette Michallet, 215612

REAL-WORLD OUTCOMES IN TRANSPLANT INELIGIBLE NDMM PATIENTS: RESULTS FROM A LARGE UK COHORT

EHA Learning Center, FAOUZI DJEBBARI, 215613

AMPLICON NEXT-GENERATION SEQUENCING (NGS) OF REARRANGED IMMUNOGLOBULIN (IG) LOCI IS ADVANTAGEOUS FOR CLONAL MARKER IDENTIFICATION AND MINIMAL RESIDUAL DISEASE (MRD) DETECTION IN MULTIPLE MYELOMA (MM).

EHA Learning Center, Michaela Kotrová, 215628

A PHASE 1B STUDY USING THE COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASOME IN MULTIPLE MYELOMA PATIENTS PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS

EHA Learning Center, Cristina Gasparetto, 215629

BOARDING ON THE SECRETARY PATHWAY IS REQUIRED FOR THE ONCOGENIC PROPERTY OF MUTANT CALRETICULIN

EHA Learning Center, Marito Araki, 215643

PHARMACOLOGICAL INHIBITION OF IGF1R/IRS TARGETING STAT3/STAT5 SIGNALING HAS ANTI-NEOPLASTIC EFFECTS IN JAK2 V617F MYELOPROLIFERATIVE NEOPLASMS

EHA Learning Center, Jaqueline Fernandes, 215644

IN VIVO INHIBITION OF JAKS IN MYELOFIBROSIS IMPROVES MONOCYTES DIFFERENTIATION AND REACTIVATES PRO-INFLAMMATORY RESPONSE IN INFECTION-STIMULATED MONOCYTES

EHA Learning Center, Lucia Catani, 215645

LIMITATIONS OF PREVIOUS PROGNOSTIC MODELS FOR THROMBOSIS AND EXPLORATION OF MODIFIED MODELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

EHA Learning Center, Yoshinori Hashimoto, 215659

SERVICE EVALUATION OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM AND SPLANCHNIC VEIN THROMBOSIS (MPN-SVT).

EHA Learning Center, Sarah Wharin, 215660

FAMILIAL MYELOPROLIFERATIVE NEOPLASMS: A SINGLE-INSTITUTION ANALYSIS OF 22 FAMILIES

EHA Learning Center, Margherita Maffioli, 215661

SPLENIC MARGINAL ZONE B-CELL LYMPHOMAS DEPENDS ON PROGRAMMED DEATH-LIGAND 1 FOR CLONAL EMERGENCE AND ARE CONTROLLED BY T-CELLS FOR PROLIFERATION RATE

EHA Learning Center, Nathalie FAUMONT, 215676

MECHANISMS CONFERRING RESISTANCE TO VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA

EHA Learning Center, Daniela Steinbrecher, 215677

CLINICAL, PATHOLOGICAL AND MOLECULAR STUDY OF 46 PATIENTS WITH A DIAGNOSIS OF CD5-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA.

EHA Learning Center, Vincent Allain, 215678

PREDICTIVE FACTORS FOR DEVELOPING SYSTEMIC LUPUS ERYTHEMATOSUS AFTER CHILDHOOD AUTOIMMUNE CYTOPENIA

EHA Learning Center, Nathalie Aladjidi, 215693

THE POLYMORPHISM OF CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 9 GENE MAY CONTRIBUTE TO RISK OF IMMUNE THROMBOCYTOPENIA

EHA Learning Center, Zi Sheng, 215694

FEATURES OF PRN1008, A BRUTON’S TYROSINE KINASE INHIBITOR, IN CLINICAL DEVELOPMENT FOR IMMUNE THROMBOCYTOPENIC PURPURA

EHA Learning Center, Steven Gourlay, 215695

THE IMPACT OF HIGH MOBILITY GROUP BOX 1 IN THE PATHOGENESIS OF IMMUNE THROMBOCYTOPENIA

EHA Learning Center, Mehmet Baysal, 215709

WHAT ARE THE UNDERLYING CAUSES AND CLINICAL CHARACTERISTICS OF CHILDREN WITH REACTIVE THROMBOCYTOSIS AT A KOREAN TERTIARY MEDICAL CENTER?

EHA Learning Center, Ye Jee Shim, 215710

STUDIES ON PLATELET FUNCTION IN A GROUP OF CLL PATIENTS DURING THE FIRST YEAR OF IBRUTINIB TREATMENT

EHA Learning Center, Bozena Sokolowska, 215712

VENETOCLAX IMPROVES QUALITY OF LIFE FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Learning Center, Tara Cochrane, 215726

NO ASSOCIATION BETWEEN INDOOR RADON AND CHILDHOOD LEUKEMIA IN FRECCLE (FINNISH REGISTER-BASED CASE-CONTROL STUDY OF CHILDHOOD LEUKEMIA)

EHA Learning Center, Atte Nikkilä, 215727

CLARITHROMYCIN ADDED TO THE VCD REGIMEN CAUSES REDUCED HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE MYELOMA PATIENTS

EHA Learning Center, Lene Kongsgaard Nielsen, 215728

IMPROVEMENT OF THE MULTIDISCIPLINARY MANAGEMENT OF SICKLE CELL DISEASE PATIENTS: IMPLEMENTATION OF A SICKLE CELL DISEASE PATIENT’S CLINICAL DATABASE: BELGIAN REGISTER OF SICKLE CELL DISEASE PATIENTS

EHA Learning Center, Beatrice Gulbis, 215743

VARIATIONS IN COMPLICATIONS RELATED TO VASO-OCCLUSIVE CRISES AND HYDROXYUREA USE IN PATIENTS WITH SICKLE CELL DISEASE: OBSERVATIONS FROM STUDIES IN THE USA, SPAIN AND THE GULF REGION

EHA Learning Center, Elena Cela, 215744

CORRELATION BETWEEN HEMOLYSIS AND HYPERCOAGULABILITY MARKERS AND EFFECTS OF HYDROXYUREA THERAPY IN SICKLE CELL PATIENTS

EHA Learning Center, Maria de Fátima Sonati, 215745

EFFICACY AND SAFETY OF DEFIBROTIDE BY VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) DIAGNOSTIC CRITERIA IN AN EXPANDED-ACCESS (T-IND) STUDY

EHA Learning Center, Selim Corbacioglu, 215759

PLASMA PRESEPSIN LEVEL IS A PREDICTIVE MARKER OF SEVERE ACUTE GVHD AFTER ALLO-HSCT: USEFULNESS AS A BIOMARKER OF ALLO-HSCT RELATED COMPLICATION

EHA Learning Center, Tatsuo Oyake, 215760

ROLE OF IFN-GAMMA IN IMMUNE-MEDIATED GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Learning Center, Pietro Merli, 215761

REGRESSION TREE BASED MODEL FOR PREDICTING NON-RELAPSE MORTALITY IN AML PATIENTS ALLO-TRANSPLANTED IN FIRST COMPLETE REMISSION

EHA Learning Center, Anish Puliyayil, 215775

COMPARISON OF BUSULFAN/CYCLOPHOSPHAMIDE ALONE AND IN COMBINATION WITH THIOTEPA OR ANTI-THYMOCYTE GLOBULIN ON HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOME AMONG BETA-THALASSEMIA PATIENTS

EHA Learning Center, Saqib Ansari, 215776

SECOND TRANSPLANT FOR PRIMARY GRAFT FAILURE , FOLLOWING HAPLOIDENTICAL GRAFTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE

EHA Learning Center, SABRINA GIAMMARCO, 215777

LOW-DOSE INTERLEUKIN-2 RESTORING HUMAN REGULATORY T CELL FUNCTION IN VITRO AS A POTENTIAL APPLICATION FOR GVHD THERAPY AFTER TRANSPLANTATION

EHA Learning Center, Tzeon-Jye Chiou, 215791

HYPOFRACTIONATED TOTAL LYMPHOID IRRADIATION BY HELICAL TOMOTHERAPY AND HIGH DOSE CHEMOTHERAPY AS CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA

EHA Learning Center, Fabio Guolo, 215792

THE RELATIONSHIP BETWEEN SELECTIVE PRE-TRANSPLANTATION IMMUNE PARAMETERS AND EARLY INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES UNDERGOING ASCT – PRELIMINARY REPORT

EHA Learning Center, Agnieszka Szymczyk, 215793

COMPREHENSIVE SCREENING FOR COEXISTING HETEROZYGOUS Α0-THALASSEMIA IN HEMOGLOBIN E TRAIT

EHA Learning Center, Piroonrut Wongprachar, 215808

ARE ALL DIRECT ORAL ANTICOAGULANTS EQUAL TO SAFETY AND EFFICACY?

EHA Learning Center, Begoña Navarro Almenzar, 215809

ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA AND ACUTE PANCREATITIS: VARIABLE AND RECIPROCAL PATHOPHYSIOLOGIC RELATIONSHIPS

EHA Learning Center, Qian (Janie) Qin, 215810

BACTERIAL CONTAMINANTS AND BIOFILMS EFFECT PLATELET ACTIVATION AND FUNCTION: IMPLICATIONS IN PLATELET TRANSFUSIONS

EHA Learning Center, Joels Wilson-Nieuwenhuis, 215824

ALLOIMMUNIZATION TO D AND NON-D RHESUS ANTIGENS INDUCED BY PLATELET TRANSFUSIONS

EHA Learning Center, Michael Daskalakis, 215825

MASSIVE TRANSFUSION PROTOCOLS - FRIEND OR FOE ?

EHA Learning Center, Moon Ley Tung, 215826

MIR-497~195 CLUSTER IS ASSOCIATED WITH FAVORABLE OUTCOME AND HAS A TUMOR SUPPRESSIVE FUNCTION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Learning Center, Elena Boldrin, 215890

RELEVANCE OF PRE AND POST TRANSPLANT PET AND HASENCLEVER INDEX IN PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANT FOR HODGKIN LYMPHOMA

EHA Learning Center, Siddharth Turkar, 215904

A REAL WORLD STUDY OF CLINICAL CHARACTERISTICS AND TREATMENT OUTCOME OF HODGKIN LYMPHOMA IN MALAYSIA: A SINGLE CENTER EXPERIENCE IN A RESOURCE LIMITED SETTING

EHA Learning Center, Tze Shin Leong, 215905

INTESTINAL COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE PATHOGENS IN HEMATOLOGICAL PATIENTS: REAPPRAISAL OF SELECTIVE ORAL DECONTAMINATION

EHA Learning Center, Igor Stoma, 215906

HEMATOLOGICAL PHENOTYPES OF DIFFERENT ALPHA-THALASSAEMIA GENOTYPES CAUSING HYPOCHROMIC MICROCYTIC ANEMIA AT NEONATAL PERIOD

EHA Learning Center, thidarat suksangpleng, 215920

INVOLVEMENT OF LEUCOCYTE DERIVED EXTRACELLULAR VESICLES IN THE PROCOAGULANT STATE FOUND IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA-RELATED CONDITION

EHA Learning Center, Adeline Wannez, 215921

INCREASED PLATELET RESPONSE TO ENDOGENOUS AGONISTS, IN PRE-DIABETIC C57BL/6 MICE

EHA Learning Center, Zibusiso Mkandla, 215922